RECEIVED MAY 19 2003 TC 1700



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

: Jackowski et al.

INVENTION:

: MACROGLOBULIN BIOPOLYMER MARKERS

INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER

: 09/993,295

RECEIVED

FILING DATE

: November 23, 2001

MAY 2 2 2003

EXAMINER:

: (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT

: 1741

ATTORNEY DOCKET NO.

: 2132.099

TRANSMITTAL LETTER

CERTIFICATE UNDER 37 CFR 1.8(a) I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Please find enclosed for filing:

Supplemental Information Disclosure Statement

Certification Pursuant to 37 C.F.R. §1.97(e)

 $\frac{X}{X}$ Copy of International Search Report

PTO-1449

References

Respectfully submitted,

Date: 5/12/2003

ર્

By:

Ferris H. Lander

Registration No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402

Palm Beach Gardens, FL 33410 Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

MAY

2 1700

IN RE APPLICANT

: Jackowski et al.

INVENTION:

: MACROGLOBULIN BIOPOLYMER MARKERS

INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER

: 09/993,295

RECEIVED

FILING DATE

: November 23, 2001

MAY 2 2 2003

EXAMINER:

: (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT

: 1741

ATTORNEY DOCKET NO.

: 2132.099

CERTIFICATION PURSUANT TO 37 C.F.R. §1.97 (e)

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §1.97(e), Applicants hereby certify that each item of information contained in the accompanying Supplemental Information Disclosure Statement filed concurrently herewith was cited in a communication from a foreign patent office, namely an International Search Report for a counterpart European patent application, not more than three months prior to the filing of the accompanying Supplemental Information Disclosure Statement.

Accordingly, pursuant to 37 C.F.R. §1.97(e), Applicants request consideration and entry of the Supplemental Information Disclosure Statement.

Date:

5/12/2003

Respectfully Submitted

Ferris H. Lander Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICANT

- : Jackowski et al.

INVENTION:

: MACROGLOBULIN BIOPOLYMER MARKERS

INDICATIVE OF INSULIN RESISTANCE

SERIAL NUMBER

: 09/993,295

RECEIVED

FILING DATE

: November 23, 2001

MAY 2 2 2003

EXAMINER:

: (not assigned yet)

TECH CENTER 1600/2900

GROUP ART UNIT

: 1741

ATTORNEY DOCKET NO.

: 2132.099

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

CERTIFICATE UNDER 37 CFR 1.8(a)
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class mail in an envelope addressed to Commissioner for Patents P.O. Box 1450, Alexandria, VA 22313-1450 on

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

5/12/2003

Sir:

Pursuant to the Duty to Disclose under 37 C.F.R. §1.56, the references cited on the accompanying form PTO-1449 are hereby brought to the attention of the Examiner for independent evaluation. A copy of each reference is enclosed. The references were cited in an International Search Report of the European Patent Office in the corresponding patent application.

A copy of the International Search Report is also enclosed, which satisfies the requirement for a concise statement of relevancy pursuant to M.P.E.P. §609 (1995).

Applicants submit that the present invention is patentable over these references.

Date

Respectfully Submitted,

Férris H. Lander Reg. No. 43,377

McHale & Slavin, P.A.

4440 PGA Boulevard, Suite 402 Palm Beach Gardens, FL 33410

Telephone: (561) 625-6575



INFORMATION DISCLOSURE STATEMENT

BY APPLICANT

Form PTO-1449 (Rev. 2-88)

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. 2132.099

APPLICATION NO. 09/993,295

Sheet 1 of 1

APPLICANT

JACKOWSKI et al.

FILING DATE

GROUP

1741 11/23/01 (Use several sheets if necessary) **U.S. PATENT DOCUMENTS** EXAMINER'S INITIAL SUBCLASS FILING DATE
F APPROPRIATE DOCUMENT NUMBER DATE NAME CLASS 12/01 6,329,500 Webb et al. MAY 2 2 2003 TECH CENTER 1600/2900 SUBCLASS TRANSLATION DOCUMENT NUMBER DATE COUNTRY CLASS YES NO 08/02 **PCT** Х WO 02/059604\ X WO 98/07036 Х 02/98 PCT OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) Van Cool, "α2-Macroglobulin Expression in Neuritic-Type Plaques in Patients With Alzheimer's Disease", Neurobiology of Aging (1993) Vol. 14, No. 3, pp. 233-237. Ahmad, et al., "A Study of Plasma Alpha-2-Macroglobulin Levels in Type 2 Diabetic Subjects with Microalbuminuria", J. Assoc. Physicians of India (2001), Vol. 49, pp. 1062-1065. Sesboue, et al., "Quantitative study of human blood alpha-1-antitrypsin, alpha-2-macroglobulin and inter-alpha-trypsin-inhibitor with respect to plasma renin activity", Clinica Chimica Acta (1983) Vol. 135, No. 1, pp. 23-34. DATABASE EMBL"Online! Teich et al., "Alpha-2-macroglobulin (fragment)", retrieved from Y EMBL, Database accesion no. Q9BQ22, XP-002237293. DATE CONSIDERED EXAMINER

* EXAMINER: Initial if a citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.